The importance of local control management in high-risk neuroblastoma in South Africa.


Journal

Pediatric surgery international
ISSN: 1437-9813
Titre abrégé: Pediatr Surg Int
Pays: Germany
ID NLM: 8609169

Informations de publication

Date de publication:
Apr 2020
Historique:
accepted: 07 02 2020
pubmed: 1 3 2020
medline: 22 9 2020
entrez: 1 3 2020
Statut: ppublish

Résumé

To investigate the impact of local therapies on high-risk neuroblastoma (HR-NB) outcomes in South Africa. Data from 295 patients with HR-NB from nine pediatric oncology units between 2000 and 2014 were analysed. All patients received chemotherapy. Five-year overall (OS) and event free survival (EFS) were determined for patients who had received local therapy, either surgery or radiotherapy or both. Surgery was performed in only 35.9% (n = 106/295) patients. Surgical excision was done for 34.8% (n = 85/244) of abdominal primaries, 50.0% (n = 11/22) of thoracic primaries; 22.2% (n = 2/9) neck primaries and 66.7% (n = 8/12) of the paraspinal primaries. Only 15.9% (n = 47/295) of all patients received radiotherapy. Children, who had surgery, had an improved five-year OS of 32.1% versus 5.9% without surgery (p < 0.001). Completely resected disease had a five-year OS of 30.5%, incomplete resections 31.4% versus no surgery 6.0% (p < 0.001). Radiated patients had a five-year OS of 21.3% versus 14.2% without radiotherapy (p < 0.001). Patients who received radiotherapy without surgical interventions, had a marginally better five-year OS of 12.5% as opposed to 5.4% (p < 0.001). Patients who underwent surgery had a longer mean overall survival of 60.9 months, while patients, who were irradiated, had a longer mean overall survival of 7.9 months (p < 0.001). On multivariate analysis, complete metastatic remission (p < 0.001), surgical status (p = 0.027), and radiotherapy status (p = 0.040) were significant predictive factors in abdominal primaries. Surgery and radiotherapy significantly improve outcomes regardless of the primary tumor site, emphasizing the importance of local control in neuroblastoma.

Identifiants

pubmed: 32112128
doi: 10.1007/s00383-020-04627-x
pii: 10.1007/s00383-020-04627-x
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

457-469

Références

J Clin Oncol. 2017 Aug 1;35(22):2580-2587
pubmed: 28471719
J Pediatr Surg. 2004 Mar;39(3):412-7; discussion 412-7
pubmed: 15017562
Eur J Cancer. 2009 Jan;45(1):90-8
pubmed: 18996003
J Clin Oncol. 1991 Sep;9(9):1599-608
pubmed: 1831494
Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1549-54
pubmed: 19211198
Pediatr Clin North Am. 2008 Feb;55(1):97-120, x
pubmed: 18242317
Pediatr Blood Cancer. 2015 Sep;62(9):1543-9
pubmed: 25820608
J Clin Oncol. 2012 May 20;30(15):1842-8
pubmed: 22529259
Pediatr Blood Cancer. 2015 Aug;62(8):1305-16
pubmed: 25810263
Pediatr Blood Cancer. 2015 Sep;62(9):1529-35
pubmed: 25810376
Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1204-1209
pubmed: 29439882
Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):806-812
pubmed: 28244417
J Pediatr Surg. 1994 Feb;29(2):128-33
pubmed: 8176583
J Clin Oncol. 2017 Jan 10;35(2):208-216
pubmed: 27870572
Semin Pediatr Surg. 2016 Oct;25(5):323-332
pubmed: 27955737
Strahlenther Onkol. 2006 Jul;182(7):389-94
pubmed: 16826357
Surgery. 1988 Jul;104(1):34-40
pubmed: 3388178
J Pediatr Surg. 2010 Apr;45(4):678-86
pubmed: 20385270
Ann Surg Oncol. 1995 Mar;2(2):93-100
pubmed: 7728576
Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):839-45
pubmed: 24867534
J Pediatr Surg. 1996 Apr;31(4):516-9
pubmed: 8801303
Pediatr Hematol Oncol. 2014 Nov;31(8):703-16
pubmed: 25247398
Pediatr Blood Cancer. 2017 Nov;64(11):
pubmed: 28440012
Cochrane Database Syst Rev. 2015 May 19;(5):CD010774
pubmed: 25989478
J Clin Oncol. 1993 Aug;11(8):1466-77
pubmed: 8336186
J Clin Oncol. 1996 Sep;14(9):2417-26
pubmed: 8823319
Semin Pediatr Surg. 2013 Aug;22(3):154-60
pubmed: 23870210
Trop Doct. 2017 Oct;47(4):370-374
pubmed: 28403698
Int Arch Med. 2010 Dec 24;3:37
pubmed: 21182799

Auteurs

Jaques van Heerden (J)

Paediatric Haematology and Oncology, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Tygerberg Hospital, Stellenbosch University, Cape Town, South Africa. Jaques.vanheerden@uza.be.

Mariana Kruger (M)

Paediatric Haematology and Oncology, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Tygerberg Hospital, Stellenbosch University, Cape Town, South Africa.

Tonya Esterhuizen (T)

Biostatistics Unit, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa.

Marc Hendricks (M)

Department of Paediatrics and Child Health, Faculty of Health Sciences, Paediatric Haematology and Oncology Service, Red Cross War Memorial Children's Hospital, University of Cape Town, Cape Town, South Africa.

Jennifer Geel (J)

Division of Paediatric Haematology and Oncology, Department of Paediatrics and Child Health, Faculty of Health Sciences, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand, Johannesburg, South Africa.

Ané Büchner (A)

Paediatric Haematology and Oncology, Department of Paediatrics, Steve Biko Academic Hospital, University of Pretoria, Pretoria, South Africa.

Gita Naidu (G)

Division of Paediatric Haematology and Oncology, Department of Paediatrics and Child Health, Faculty of Health Sciences, Chris Hani Baragwanath Academic Hospital, University of the Witwatersrand, Johannesburg, South Africa.

Jan du Plessis (J)

Division of Paediatric Haematology and Oncology, Department of Paediatrics, Faculty of Health Sciences, Universitas Hospital, University of the Free State, Bloemfontein, South Africa.

Barry Vanemmenes (B)

Division of Paediatric Haematology and Oncology Hospital, Department of Paediatrics, Frere Hospital, East London, South Africa.

Ronelle Uys (R)

Paediatric Haematology and Oncology, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Tygerberg Hospital, Stellenbosch University, Cape Town, South Africa.

G P Hadley (GP)

Department of Paediatric Surgery, Faculty of Health Sciences, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH